Table 1 Study design

From: Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP

Week

Group 1 (n = 13)R-R-R

Group 2 (n = 13)R-R-r

Group 3 (n = 13)RA-RM-RM

Group 4 (n = 13)RA-RM-rM

Group 5 (n = 4)Control

0

RTS,S/AS01B (Standard dose)

RTS,S/AS01B (Standard dose)

RTS,S/AS01B (Standard dose) and ChAd63 ME-TRAP

RTS,S/AS01B (Standard dose) and ChAd63 ME-TRAP

 

4

RTS,S/AS01B (Standard dose)

RTS,S/AS01B (Standard dose)

RTS,S/AS01B (Standard dose) and MVA ME-TRAP

RTS,S/AS01B (Standard dose) and MVA ME-TRAP

 

8

RTS,S/AS01B (Standard dose)

RTS,S/AS01B (1/5 Standard dose)

RTS,S/AS01B (Standard dose) and MVA ME-TRAP

RTS,S/AS01B (1/5 Standard dose) and MVA ME-TRAP

 

11

CHMI (n = 12)

CHMI (n = 12)

CHMI (n = 12)

CHMI (n = 12)

CHMI

  1. Group 1 received 3 standard doses (50 µg) of RTS,S/AS01B (R-R-R); Group 2 received two standard doses of RTS,S/AS01B followed by a third fractional dose of RTS,S/AS01B at 1/5th of the standard dose (R-R-r); Group 3 received three standard doses of RTS,S/AS01B in addition to ChAd63 ME-TRAP 5 × 1010 virus particles (vp) at week 0 and MVA ME-TRAP 2 × 108 plaque-forming units (PFU) at weeks 4 and 8 (RA-RM-RM); Group 4 received two standard doses of RTS,S/AS01B followed by a third fractional dose of RTS,S/AS01B at 1/5th of the standard dose in addition to ChAd63 ME-TRAP 5 × 1010 vp at week 0 and MVA ME-TRAP 2 × 108 PFU at weeks 4 and 8 (RA-RM-rM). Group 5 (n = 4) received no vaccinations
Back to article page